wyeth Pristiq Low Dose Data Poster

This document summarizes the results of two randomized, double-blind, placebo-controlled clinical trials that evaluated the efficacy and safety of fixed doses of 50 mg and 100 mg of the serotonin-norepinephrine reuptake inhibitor desvenlafaxine succinate for the treatment of major depressive disorder. The trials found that both the 50 mg and 100 mg doses were more effective than placebo at reducing depression symptoms, based on evaluations of depression rating scales. The most common adverse events reported with desvenlafaxine treatment were dry mouth, nausea, dizziness, insomnia, and constipation. Discontinuation rates due to adverse events were higher with desvenlafaxine than placebo.